JSPR stock forecast, quote, news & analysis
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma... Show more
Why Jasper Therapeutics (JSPR) Stock Is Down 10% in the Last 30 Days
Key Takeaways
- Jasper Therapeutics shares declined roughly 10% over the last 30 days on a split-adjusted basis, extending a longer slide for the clinical-stage biotechnology company.
- The move coincided with a 1-for-30 reverse stock split that became effective November 6, 2026, taken after the stock traded well below the $1.00 Nasdaq minimum bid threshold.
- Over the trailing quarter, the stock is down approximately 36%, reflecting persistent cash burn, dilution concerns, and the absence of commercial-stage revenue.
- Recent clinical progress, including completed enrollment in the IgA nephropathy (IgAN) cohort of the Phase 2 KP104 renal basket study, has not yet offset selling pressure.
- Near-term catalysts include initial Stage 1 IgAN data expected by year-end 2026 and an FSGS expansion cohort anticipated to begin dosing in the first quarter of 2027.
- For additional detail, review Jasper's Price Targets, Earnings, and Forecast on Tickeron's dedicated pages.
- Explore Tickeron's Trending AI Robots to see how AI-driven trading strategies approach JSPR and thousands of other tickers.
Jasper Therapeutics (JSPR) Company Overview and Market Position
Jasper Therapeutics is a clinical-stage biotechnology company headquartered in Redwood City, California, and founded in 2018. It develops therapies targeting mast cell-driven and other immune-mediated diseases. Its lead candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor signaling through the CD117 (c-KIT) receptor and is being evaluated in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma. The company is also advancing vensobufasp alfa (KP104), a dual-complement inhibitor in Phase 2 development for paroxysmal nocturnal hemoglobinuria (PNH) and IgA nephropathy (IgAN). As a pre-revenue developer, Jasper relies on its cash position and access to capital markets to fund research, which makes the shares highly sensitive to dilution, financing activity, and binary clinical data readouts.
Jasper Therapeutics (JSPR) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, JSPR fell roughly 10%, moving from a split-adjusted close of about $17.11 on October 9, 2026, to approximately $15.35 in recent trading. Because the company completed a 1-for-30 reverse stock split on November 6, 2026, pre-split prices are adjusted to allow a like-for-like comparison; the split itself does not change shareholder value but multiplied the quoted share price and reduced the share count.
The decline is part of a broader, multi-month downtrend. Over the trailing quarter, the stock is down approximately 36%, falling from around $23.98 in mid-August 2026. After peaking near $26.79 in mid-August, shares have trended steadily lower as the company worked through Nasdaq listing compliance issues and financing concerns.
What Drove JSPR Stock Price in the Last 30 Days
The dominant development was the reverse split. Before the split, JSPR traded in a range of roughly $0.50 to $0.57, below the Nasdaq $1.00 minimum bid price requirement, which put the listing at risk. On November 4, 2026, the company announced a 1-for-30 reverse split effective November 6, and the stock was temporarily halted pending the news. The split reduced the outstanding share count from roughly 33.3 million to about 1.1 million shares and lifted the nominal price, but it did not change the company's market capitalization, which remained near $18 million.
Dilution also weighed on sentiment. In mid-October, the company filed a registration statement covering the resale of up to 284.01 million shares by selling stockholders, and it subsequently reported results of an offer to purchase related to its warrants. Meanwhile, positive clinical news, including completion of enrollment in the IgAN cohort of the Phase 2 KP104 renal basket study, provided only temporary support amid limited liquidity and broad volatility in micro-cap biotech names.
What Drove JSPR Stock Performance Over the Last Quarter
The quarterly decline reflects a convergence of structural pressures rather than a single event. Jasper reported its second-quarter 2026 results in mid-August, with continued operating losses and no product revenue, typical of a pre-commercial biotech. With a cash-intensive pipeline and recurring financing needs, investors have been repricing the shares against the risk of future dilution and the company's ability to fund its clinical programs.
The slide toward and below the $1.00 threshold also forced the company to pursue the reverse split to maintain Nasdaq compliance, a step often viewed as a signal of distress among micro-cap issuers. Clinical updates, including progress on KP104 in IgAN and the plan to add an FSGS expansion cohort, have kept the long-term narrative intact but have not reversed the near-term technical and financing-driven weakness.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots drawn from a library of hundreds that monitor thousands of tickers. Only the top-performing and most relevant bots appear in this section, allowing traders to quickly scan strategies that have demonstrated strength in current market conditions. The bots vary by strategy, holding timeframe, and performance metrics, ranging from short-term momentum approaches to longer-horizon models, giving users a way to compare automated approaches without building their own systems. For investors following JSPR and similar names, the page offers a way to explore how algorithmic strategies are positioning across the market.
JSPR Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor several data points in the months ahead. The most significant near-term catalyst is initial Stage 1 data from the IgAN cohort of the Phase 2 KP104 renal basket study, which the company expects by year-end 2026, followed by first patient dosing in an FSGS expansion cohort anticipated in the first quarter of 2027. The company's next quarterly earnings report will provide updated cash runway and research-and-development spending figures, which matter for a pre-revenue developer. Continued Nasdaq compliance after the reverse split, the pace of any additional capital raises or share resales, and broader biotech and interest-rate sentiment are also likely to influence the stock. These are risk factors rather than forecasts, and outcomes remain uncertain.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for JSPR turns negative, indicating new downward trend
JSPR saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned negative. In 84 of the 92 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JSPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
JSPR broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JSPR entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for JSPR just turned positive on October 23, 2026. Looking at past instances where JSPR's MACD turned positive, the stock continued to rise in 32 of 37 cases over the following month. The odds of a continued upward trend are 86%.
Following a +6.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where JSPR advanced for three days, in 203 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. JSPR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: JSPR's P/B Ratio (397.034) is very high in comparison to the industry average of (3.498). P/E Ratio (-18.129) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JSPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology